

Corporate Overview

May 2019

This material has been made available to you with the consent of ShockWave Medical, Inc. for informational purposes only.

This presentation is for you to familiarize yourself with the company. This presentation may not be reproduced or redistributed in whole or in part nor may its contents be disclosed to any other person.

This presentation includes forward-looking statements. All statements contained in this presentation other than statements of historical facts, including our business strategy and plans and our objectives for future operations, including our financial performance, are forward-looking statements. The words "anticipate," believe," "continue," "estimate," "expect," "intend," "may," "will" and similar expressions are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives, and financial needs. These forward-looking statements are subject to a number of risks and uncertainties. The future events and trends discussed in this presentation may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance, achievements or events and circumstances reflected in the forward-looking statements will occur. Except to the extent required by law, we do not undertake to update any of these forward-looking statements after the date of this presentation to conform these statements to actual results or revised expectations.

This presentation also contains estimates and other statistical data made by independent parties and by us relating to market size and growth and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. Neither we nor any other person makes any representation as to the accuracy or completeness of such data or undertakes any obligation to update such data after the date of this presentation. In addition, projections, assumptions and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk.





Seeking to transform the treatment of calcified cardiovascular disease

Seeking to establish a new standard of care through intravascular lithotripsy (IVL)

Differentiated and proprietary local delivery of sonic pressure waves for the treatment of calcified plaque






Goal of Vascular Intervention: Restore Vessel Size and Blood Flow

Atherosclerosis

Disease of aging in which arteries become narrowed ("stenotic") by the progressive growth of plaque.

Calcium in atherosclerotic plaque can prevent therapies from opening the stenotic artery.



Calcium

Medial ("Deep") Calcium

Calcification in middle layer (associated with stiffening)

Intimal ("Superficial") Calcium

Calcification close to the inner surface of the artery (associated with obstruction and embolization)



* Stent struts

Calcified Arteries Resist Expansion Resulting in More Complications and Vessel Damage

Proxima



Common Risks with Traditional Methods to Treat Calcified Atherosclerosis



Risks

- Dissection
- Perforation
- Restenosis (from tissue damage)

Risks

- Embolism
- Dissection
- Perforation
- Restenosis (from tissue damage)

Risks

- Dissection
- Perforation
- Restenosis (from tissue damage)

There is a Need for Devices to Safely and Easily Prepare Calcified Arteries



Lithotripsy Has a History of Safely Cracking Calcium

Lithotripsy


Method has 30 years of success for safe elimination of kidney stones

Sonic pressure waves preferentially crack calcium without harming soft tissue Shockwave's Cardiovascular Lithotripsy

Miniaturized, localized treatment

Sound waves pass through soft tissue to crack calcium

Vessel expands under low pressure






Our Solution: Intravascular Lithotripsy



- Miniaturized local treatment
- Expands vessel under low pressure
- Treats both superficial and deep calcium
- Improves safety; no harm to soft tissue
- Improves stent expansion
- Easily integrates into interventional practice
- Expands access to interventional techniques
- Meaningful cost-saving potential



IVL is Uniquely Able to Address Superficial and Deep Calcium Low pressure inflation reduces dissection risk



Standard Interventional Techniques Encourage Adoption




Why Shockwave

Safe	Treating most complex calcified anatomies with virtually no complications
Simple	Every interventional operator can use IVL (OR: No learning curve)
Effective	Unique mechanism of action that cracks both medial and intimal calcium



Targeted Segments Have a TAM of >\$6 Billion



1. Annual procedures in the United States and internationally (nine European countries, five Asian countries), according to DRG and Company estimates; Proportion of annual procedures associated with calcified disease, according to Yost, M. L., Prevalence and Significance of Calcium, Vulnerable Plaque and Plaque Morphology in Peripheral Artery Disease (PAD). Beaufort, SC: THE SAGE GROUP; 2016 (for femoropopliteal, BTK, TAVR and common femoral) and Company estimates based on multiple occlusive disease studies (for iliac and EVAR / TEVAR).2 Annual procedures in 2025 according to the Journal of Thoracic Disease,2017;9(6):1432-1436




10

IVL Can Grow Markets and Take Share

Peripheral Artery Disease (PAD)	Coronary Artery Disease (CAD)	Aortic Stenosis (AS)
Market Growth	Market Growth	Market Growth
🕗 Iliac	🕑 Left Main	✓ Very Old/Frail
Common Femoral	Ostial Lesions	Contraindicated for TAVR
"Large Bore" Access	Iigh-Risk PCI	Co-Morbidities
Selow-the-Knee	Standard" Cardiologists	Young Patients
Potential Shockwave Share Gain	Share Gain	Share Gain
Semoropopliteal (SFA)	✓ All cross-able lesions	✓ TAVR Procedures
Below-the-Knee		







Shockwave Clinical Study Highlights




SHOCKWAVE

13

Key Advantage of Shockwave IVL: Safety

IVL Delivered Via a Low-Pressure Balloon Provides Exceptional Safety






1. Disrupt PAD II Study, data on file at company 2. Disrupt CAD I Study, data on file at company

Disrupt CAD III Trial – Enrollment Initiated

Multicenter, prospective, non- randomized trial (50 clinical sites in U.S. and Europe)



FDA Approval of C²



Commercialization Strategy


Two paths for growth: procedure share and expansion into new indications

United States

58 professionals on sales & marketing team¹

Mix of direct sales reps and clinical specialists

Low service burden enables cost efficient sales model



International

Direct sales Germany, Austria, Switzerland

Distributors in Australia, the Baltics, Canada, Czech Republic, France, Italy, Netherlands, New Zealand, the Nordic region, Poland, Spain, Middle East, Hong Kong, South Africa and the UK

Similar Call Points for Vascular IVL Catheters Allowing Further Leverage of Field Sales Team



Multiple Catalysts for Growth

	Near Term Catalysts (1H 2019)	Medium Term Catalyst (2H 2019)	ts Long Term Catalysts (2020 – 2021)
ATK (M⁵)	 ABMD collaboration U.S. launch Multiple publications 		PAD III clinical data (2020)
BTK (S ⁴)		► Launch new S ⁴ catheters	
CAD (C ²)	Initiation of CAD IIICAD I publication	 Global expansion 	 CAD III data (2H 2020) U.S. launch (1H 2021) Japan launch (mid 2021)
Aortic Stenosis	 Initiate FIM3 study in Austra 	llia	 6-month (Q1 '20) data from FIM3 1-yr (Q4 '20) data from FIM3




IVL Drives Economic Value for Hospitals

Reduced time required by physicians to understand and adopt our system

Reduced need for complex, risky and expensive procedures for additional devices and potential complications


Reduced costs associated with complications that lead to high supply costs and lower profitability



Time Savings

Procedure Savings

Hospital Savings



Dartmouth-Hitchcock, "Lesion complexity drives the cost of superficial femoral artery endovascular interventions," J Vasc Surg. 2015 October; 62(4): 998–1002. 10.10.16/j.jvs.2015.04.450 and VIVA 2017 Presentation by Richard Powell "How Does Tracking Quality, Training, Experience and Outcomes Lower Procedural Costs Across Vascular Specialties?", Slides 15 & 17
 Information on loss is for illustrative purposes only; actual results & data may differ



Operational Excellence

- Headquarters located in Santa Clara, CA
- European subsidiary in Germany
- Third party logistics provider based in the Netherlands
- 180+ employees¹
- Lean manufacturing expected to drive margin expansion
- 50+ manufacturing employees¹
- Specialized sales force fosters deep relationships
- Marketed products in 30 countries and growing
- Robust IP portfolio of 75 issued and 47 pending patents¹






Strong Financial Profile

Annual Results

Revenue CAGR: 350%

First Quarter Results

Revenue Growth¹: 450%



Q1 2019 Performance

- 1Q 2019 revenue growth of 450% year over year
- Increase in gross margin to 58% in 1Q 2019

2019 Expectations

 2019 annual revenue guidance \$33M - \$36M²

¹ Unaudited financial results

² Represents the Company's publicly disclosed guidance as of May 8, 2019. This presentation should not be construed as an update to such guidance.

Growth Drivers

Advance Clinical Evidence

- Demonstrate that IVL is standard of care for calcified arteries
- Expand indications
- Improve economic story

Expand Commercial Capabilities

- Increase direct and distributor field sales organization
- Grow across indications and geographies
- Initiate broader Medical Affairs initiatives

Scale Business • New products • Increase interventional

- procedures by addressing unmet clinical needs
- Partnerships for mutually beneficial outcomes
- Scale efficiencies to improve profitability



Investment Highlights

ADDRESSES LARGE UNMET CLINICAL NEED	Advancing proprietary IVL System for multiple large addressable markets totaling \$6B+ Optimizes existing treatment with improved outcomes and expands market with superior, effective products
DIFFERENTIATED AND COST EFFECTIVE PLATFORM	Unique mechanism of action that cracks both medial and intimal calcium Cost saving potential through reduced complications and minimal required time and training for physicians
STRONG PIPELINE	Ongoing clinical programs to expand geographies and indications and build a robust body of clinical evidence Platform IVL Technology leverageable for new products to satisfy additional significant unmet clinical needs





We Crack Calcium